The mRNA Suppliers: 93 Percent of Maravai's 2021 CleanCap Revenue Came From COVID

The operating story had another layer. The mRNA vaccines needed cap analogs, lipid nanoparticles, sterile vial filling, inspection, packaging, release testing, cold-chain logistics, and enough manufacturing discipline to turn a lab platform into billions of administered doses.

That layer created its own pandemic darlings, among them Maravai LifeSciences, Acuitas Therapeutics, and Catalent. Some were public, some were private, and some never became household names because their product sat one step upstream of the shot.

Maravai sold a critical ingredient. Acuitas supplied delivery technology. Catalent supplied manufacturing capacity at the moment when capacity was the product.

Maravai's CleanCap Moment

Maravai was a life-sciences supplier. Its TriLink BioTechnologies unit made nucleic-acid products, including CleanCap, a proprietary mRNA capping technology. That is a narrow business line until the world suddenly needs mRNA vaccine production at scale.

GTCR formed Maravai in 2014 with Carl Hull and Eric Tardif and said it would invest up to $300 million of equity capital to build a diagnostics and life-sciences platform. In 2016, Maravai acquired TriLink BioTechnologies, the business that later put CleanCap inside the mRNA supply chain.²³

The exit window came during the vaccine boom. Maravai closed its initial public offering on November 24, 2020, selling 69 million Class A shares at $27 and raising about $1.863 billion in gross proceeds. Morgan Stanley, Jefferies, and Goldman Sachs led the underwriting group.⁴

Maravai reported full-year 2021 revenue of $799.2 million, up 181 percent from 2020. Its nucleic-acid production segment generated $711.9 million in 2021, up 245 percent year over year.⁵

The company tied the fourth-quarter jump directly to CleanCap demand. Nucleic-acid production revenue was $212.5 million in the fourth quarter of 2021, up 173 percent from the prior-year quarter, driven by demand for CleanCap analogs as COVID-19 vaccine manufacturers scaled production.⁵

The SEC later pushed Maravai on how much of the CleanCap business was COVID-related. The staff's comment letter quoted Maravai's own first-quarter 2022 earnings call: CleanCap revenue from major COVID-19 vaccine customers was about $172.9 million, against $91 million a year earlier. In its July 2022 response, Maravai estimated, for full-year 2021, that about $557.4 million, or 93 percent, of its $599.1 million CleanCap revenue came from customer demand attributable to COVID-19 vaccines or other COVID-related commercial products or development programs.¹

The risk was just as concentrated. Maravai warned the SEC that CleanCap products could be used for other purposes and that it could not track ultimate end use with perfect precision. It also said future disclosure would depend on whether COVID-related CleanCap revenue remained material to understanding results. A company that looked like a general life-sciences tools business had, for a period, become a COVID-vaccine input business.

Acuitas And The Delivery Problem

The mRNA molecule needed a delivery system. Lipid nanoparticles made the platform usable.

Acuitas Therapeutics sat inside that delivery layer. Pfizer's January 2022 agreement with Acuitas described Acuitas as a Vancouver company focused on lipid nanoparticle delivery systems for mRNA-based therapeutics. Pfizer said Acuitas' clinically validated LNP technology was used in Comirnaty, the Pfizer-BioNTech COVID-19 vaccine. Pfizer also said the new agreement gave it an option to license Acuitas' LNP technology, on a non-exclusive basis, for up to 10 vaccine or therapeutic targets.⁶

Acuitas had existed long before COVID; its corporate history dates to 2009. The company was part of a delivery-technology world that included academic work, private firms, platform disputes, and patent fights, and the pandemic turned that layer into a visible strategic asset.

We found no public record of large venture rounds for Acuitas. The record shows partner agreements and public R&D support. The National Research Council Canada said Acuitas had more than five years of advisory and R&D funding support through NRC IRAP, which helped it build its internal chemistry program, hire PhD expertise, and develop its LNP system for mRNA delivery.⁷

Pfizer's 2022 Acuitas agreement was a development-and-option arrangement, not a venture round.

Delivery technology determined whether the mRNA instruction could reach cells in a form the body could use. The vaccine card did not say Acuitas.

Catalent And The Last Mile Before Distribution

The other bottleneck was physical. Once the vaccine substance existed, it still had to be filled into vials, inspected, labeled, packed, and released at speed.

Catalent was one of the major contract manufacturers in that work. In June 2020, Moderna and Catalent announced a collaboration for large-scale commercial fill-finish manufacturing of Moderna's COVID-19 vaccine candidate at Catalent's Bloomington, Indiana site. In April 2021, the companies expanded that arrangement: Catalent would dedicate a new high-speed filling line to Moderna through June 2023, with inspection, labeling, cartoning, and final packaging support.⁸

Moderna's 2021 annual report lists Catalent among the companies providing fill-finish services for Moderna's COVID-19 vaccine in the United States, along with Thermo Fisher, Sanofi, and Baxter.⁹

Catalent sold something other than a cap analog or a delivery platform: scale, sterile process, regulatory execution, and available manufacturing slots. In a normal market, those are vendor capabilities. In 2020 and 2021, they were strategic capacity.

In Operation Warp Speed-era vaccine production, industrialization was a race alongside discovery. A vaccine that works in a trial still needs plants, workers, equipment, release procedures, raw materials, and enough redundancy to survive inevitable failures.

Upstream of the public argument

These companies did not all face the same exposure. Maravai had public-company concentration risk. Acuitas remained private and technology-centered. Catalent had a broader contract-development and manufacturing business. Their common feature was placement: they were upstream of the public argument.

The vaccine brands took the politics. Pfizer and Moderna became shorthand for mandates, boosters, procurement deals, authorizations, myocarditis warnings, patent fights, and booster-market decline. The upstream suppliers were less visible and their role more technical, but the money was not smaller: Maravai's CleanCap numbers were large enough to become an SEC-disclosure issue.

Public money and emergency demand reward the company closest to the bottleneck. Sometimes that is the consumer-facing brand. Sometimes it is the processor, the lender, the identity vendor, the test distributor, the contract manufacturer, the data broker, or the supplier whose name never appears in the public-facing product.

The Post-Pandemic Test

Maravai's CleanCap surge was tied to COVID vaccine production. That does not make CleanCap a one-product story. mRNA therapeutics and vaccines may keep expanding. But the 2021-2022 volume shock came from a once-in-a-century vaccination campaign. Investors who bought the supplier story had to decide whether they were buying a temporary production spike or the permanent buildout of an mRNA industrial base.

Acuitas faced the more durable but less transparent question: how valuable is a delivery platform after the first approved mRNA vaccine proves the category? The answer depends on licenses, patents, next-generation vaccines, therapeutics, and who controls enough LNP technology to support future products.

Catalent faced the contract-manufacturing version of the same problem. Emergency capacity was precious when every sponsor was trying to secure fill-finish slots. Later, capacity could become excess capacity. In May 2026 BioNTech said it would consolidate its manufacturing network "where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech's partners' manufacturing capacities and completion of contracts," exiting sites in Idar-Oberstein, Marburg and Singapore as well as CureVac's sites, affecting up to about 1,860 positions.¹⁰

The public saw the vial. The money also moved through the cap, the particle, and the line that filled it.

Notes

1. Maravai LifeSciences response to SEC comment letter, July 12, 2022, original. ↩₁ ↩₂
2. GTCR, "GTCR Announces Partnership With Carl Hull and Eric Tardif to Form Maravai Life Sciences", Mar. 19, 2014, original. ↩
3. TriLink BioTechnologies, "Maravai LifeSciences Acquires TriLink BioTechnologies", Oct. 20, 2016, original. ↩
4. Maravai LifeSciences, "Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares", Nov. 24, 2020, original. ↩
5. Maravai LifeSciences, "Maravai LifeSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Updates 2022 Financial Guidance", Feb. 23, 2022, original. ↩₁ ↩₂
6. Pfizer, "Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics", Jan. 10, 2022, original. ↩
7. National Research Council Canada, "Producing lipid nanoparticle technology for vaccine delivery (Acuitas Therapeutics)", May 17, 2021, original. ↩
8. Catalent, "Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna's COVID-19 Vaccine and Clinical Portfolio", Apr. 6, 2021, original. ↩
9. Moderna, 2021 Form 10-K, filed Feb. 25, 2022, original. ↩
10. BioNTech, "BioNTech Announces First Quarter 2026 Financial Results and Corporate Update", May 5, 2026, original. ↩